Genomic Health, Inc.
301 Penobscot Drive
Redwood City
California
94063
United States
Tel: 650-556-9300
Fax: 650-556-1132
Website: http://www.genomichealth.com/
About Genomic Health, Inc.
About Genomic Health Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.About Oncotype DX® The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. With half a million patients tested in more than 80 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeDX.com, www.mybreastcancertreatment.org and www.myprostatecancertreatment.org.
404 articles about Genomic Health, Inc.
-
Genomic Health, Inc. Announces Positive Results In Multiple Studies Presented At The American Society of Clinical Oncology Meeting
6/6/2006
-
The National Surgical Adjuvant Breast & Bowel Project And Genomic Health, Inc. Announce Positive Early Results In Development Of Genomic Test For Colon Cancer Prognosis
6/5/2006
-
Genomic Health, Inc. Announces Multiple Posters To Be Presented At American Society of Clinical Oncology Annual Meeting
6/2/2006
-
Genomic Health, Inc. Announces Publication Of Kaiser Permanente Study Demonstrating Oncotype DX Helps Predict Likelihood Of Survival In Early-Stage Breast Cancer
5/31/2006
-
Genomic Health, Inc. Announces 'Early Release' Publication Of NSABP Study Confirming Oncotype DX Predicts Chemotherapy Benefit In Certain Breast Cancer Patients; Study Findings Pave Way For Landmark NCI TAILORx Trial
5/24/2006
-
Genomic Health, Inc. Announces 'Early Release' Publication Of NSABP Study Confirming Oncotype DX Predicts Chemotherapy Benefit In Certain Breast Cancer Patients; Study Findings Pave Way For Landmark NCI TAILORx Trial
5/23/2006
-
Genomic Health, Inc. To Present At 2006 Bank of America Health Care Conference
5/10/2006
-
Genomic Health, Inc. Announces First Quarter 2006 Financial Results And Business Progress
5/3/2006
-
Genomic Health, Inc. To Announce First Quarter 2006 Financial Results And Host Conference Call On Tuesday, May 2, 2006
4/25/2006
-
Genomic Health, Inc. Announces Appointment Of Dr. Woodrow Myers To Board Of Directors
4/11/2006
-
Genomic Health, Inc. To Participate In Panel Discussion At Biotechnology Industry Organization (BIO) 2006 National Convention
4/10/2006
-
Genomic Health, Inc. To Present At Thomson Financial And BioCentury's Future Leaders In The Biotech Industry Conference
3/23/2006
-
Genomic Health, Inc. To Present At JMP Securities Research Conference And Lehman Brothers Global Healthcare Conference
3/2/2006
-
Genomic Health, Inc. Announces Fourth Quarter And Year-End 2005 Financial Results And Business Progress
2/14/2006
-
Genomic Health, Inc. To Present At The 2006 Biotechnology Industry Organization (BIO) CEO & Investor Conference
2/10/2006
-
Genomic Health, Inc. To Announce Fourth Quarter And Year-End 2005 Financial Results And Host Conference Call On Monday, February 13, 2006
2/7/2006
-
Genomic Health, Inc. Plans To Meet With FDA In Response To Invitation
1/27/2006
-
Genomic Health, Inc. To Present At 2006 JPMorgan Healthcare Conference
1/5/2006
-
Genomic Health, Inc. Announces Study Results Demonstrating Oncotype DX(TM)'s Ability To Quantify Risk For Local And Regional Breast Cancer Recurrence
12/12/2005
-
Genomic Health, Inc. Announces Study Results Demonstrating Oncotype DX(TM) Changed Adjuvant Treatment Approach For 25 Percent Of Early-Stage Breast Cancer Patients
12/9/2005